Mindstrong Health Company raised $14 million in the first round of Financing, Series A, aimed to support the neuropsychiatric diagnosis and treatment platform. The firm utilizes smartphones to detect and help to treat neuropsychiatric disorders. Some of the main investors were Foresite Capital, Optum Ventures, One Mind Brain Health Impact Fund, and ARCH Venture Partners.
According to the CEO of Mindstrong Health, Paul Dagum, despite the fact that modern medicine is based on objective measurement, mental health has been confined to limited subjective reports in the clinical setting. People with mental illnesses need the objective measures similar to those applied to other chronic diseases such as heart disease and diabetes.
Mindstrong Health provides continuous objective measures of cognition and behavior at an insight and a high level of resolution that has never been achieved. Jim Tananbaum praised Mindstrong Health for their unsurpassed understanding of the hurdles faced by the people with cognitive health disorders.
Jim Tananbaum (officialjimtananbaum.com) is the Founder of Foresite Capital Management. The company invests in firms with services in the healthcare sector including genomics, medical devices, diagnostics, and biotechnology. Jim studied at Yale University and graduated with a bachelor’s degree in electrical engineering. Jim Tananbaum holds an MD from the Harvard Medical School and an MBA from the Harvard Business School. Currently, he serves as the CEO of Foresite Capital Management.
Jim was one of the few investors who appeared on the Forbes Midas List of top 100 investors in 2017. It was his first time to appear on the Midas list. For one to one on this list, he/she should be ready to make colossal calculations and great risks. Lucky people also find their way to this coveted list.
Jim has been in the investment industry for more than two decades. According to researchgate.net, he was part of Sierra Ventures and Prospect Ventures Partners. Jim’s leading investments include Amerigroup, Amira Pharmaceuticals, Healtheon, and Jazz Pharmaceuticals. He founded and held managerial positions at Theravance and GelTex Pharmaceuticals. Dr. Tananbaum served on the visiting committees as well as advisory boards of Yale School of Engineering and Harvard-MIT HST program.